Popular Trials
Procedure
Low-Cost Imaging for Cervical Cancer
This trial is testing a new type of medical equipment to see if it's as effective as the current equipment in diagnosing cervical pre-cancerous lesions and cancer. If it is, it could mean that patients wouldn't have to wait for biopsy results before getting treatment.
Behavioural Intervention
Nurse-Led Education for Advanced Cancer
This trial looks at a nurse-led program to help patients with worries, fears, and uncertainty. It will help researchers understand if the program is helpful and practical. This study may help patients learn more effective ways to cope.
Radiation Therapy
Palliative Radiation Therapy for Malignant Female Reproductive System Cancer
This trial studies if one radiation treatment can improve symptoms of metastatic gynecologic cancers and help patients live more comfortably. It also looks at the effects of one vs multiple treatments.
Popular Filters
Trials for Ovarian Cancer Patients
Alkylating agents
NK Cells + Cyclophosphamide + Etoposide for Solid Tumors
This trial is testing the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells, given with cyclophosphamide and etoposide, to treat children and young adults with solid tumors.
Monoclonal Antibodies
Brachytherapy + Immunotherapy for Recurrent Gynecological Cancer
This trial is studying brachytherapy with durvalumab or tremelimumab to treat patients with gynecological malignancies that is resistant to platinum therapy (platinum-resistant), does not respond to treatment (refractory), has come back (recurrent), or has spread to other places in body (metastatic).
PARP Inhibitor
Talazoparib + Radiation for Gynecologic Cancers
This trial looks at the side effects and best dose of talazoparib when given with radiation therapy for treating patients with recurrent gynecologic cancers. Talazoparib may stop cancer growth by blocking some enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib with radiation therapy may work better in treating patients with gynecologic cancers.
Checkpoint Inhibitor
Nivolumab +/- Ipilimumab for Advanced Gynecologic Cancers with Peritoneal Carcinomatosis
This trial is studying the side effects and best dose of nivolumab with or without ipilimumab to treat patients with female reproductive cancer that has come back or is high grade and has spread extensively throughout the peritoneal cavity.
Trials for SOC Patients
Alkylating agents
NK Cells + Cyclophosphamide + Etoposide for Solid Tumors
This trial is testing the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells, given with cyclophosphamide and etoposide, to treat children and young adults with solid tumors.
Monoclonal Antibodies
Brachytherapy + Immunotherapy for Recurrent Gynecological Cancer
This trial is studying brachytherapy with durvalumab or tremelimumab to treat patients with gynecological malignancies that is resistant to platinum therapy (platinum-resistant), does not respond to treatment (refractory), has come back (recurrent), or has spread to other places in body (metastatic).
PARP Inhibitor
Talazoparib + Radiation for Gynecologic Cancers
This trial looks at the side effects and best dose of talazoparib when given with radiation therapy for treating patients with recurrent gynecologic cancers. Talazoparib may stop cancer growth by blocking some enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib with radiation therapy may work better in treating patients with gynecologic cancers.
Checkpoint Inhibitor
Nivolumab +/- Ipilimumab for Advanced Gynecologic Cancers with Peritoneal Carcinomatosis
This trial is studying the side effects and best dose of nivolumab with or without ipilimumab to treat patients with female reproductive cancer that has come back or is high grade and has spread extensively throughout the peritoneal cavity.
Trials With No Placebo
Alkylating agents
NK Cells + Cyclophosphamide + Etoposide for Solid Tumors
This trial is testing the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells, given with cyclophosphamide and etoposide, to treat children and young adults with solid tumors.
MEK Inhibitor
Selumetinib + Olaparib for Cancer
This trial has two phases: in the first, they'll find the highest dose of the drugs that patients can tolerate; in the second, they'll see if that dose can help control patients' advanced or recurrent solid tumors. Safety will also be monitored in both phases.
Behavioural Intervention
Social Work Counseling for Cancer of the Female Reproductive System
This trial is testing whether social work counseling can help increase the number of people with gynecologic cancer who have a medical power of attorney, and whether it can affect their attitudes about decision-making.
View More Related Trials
Frequently Asked Questions
Introduction to genital warts
What are the top hospitals conducting genital warts research?
When it comes to clinical trials for genital warts, one hospital stands out for its dedication and commitment. Zuckerberg San Francisco General Hospital, located in the vibrant city of San Francisco, is currently conducting an active trial focused on this condition. While they do not have any recorded past trials specifically targeting genital warts, their involvement in ongoing research demonstrates a proactive approach towards finding effective solutions for those affected by this common sexually transmitted infection.
Genital warts are caused by certain strains of the human papillomavirus (HPV) and can appear as small growths or bumps in the genital area. This highly contagious condition affects both men and women and is primarily transmitted through sexual contact. Despite being a prevalent health issue worldwide, treatment options have been limited and challenging due to the stubborn nature of these warts.
By actively engaging in clinical trials related to genital wart management at Zuckerberg San Francisco General Hospital, researchers aim to explore innovative approaches that could potentially revolutionize prevention strategies or find more effective treatments. These trials often involve studying new medications or therapies that target the underlying viral infection responsible for causing genital warts.
The efforts made by institutions like Zuckerberg San Francisco General Hospital highlight the importance of scientific exploration in tackling common yet elusive conditions such as genital warts. Through their ongoing trial participation, they contribute significantly to advancing knowledge about this sexually transmitted infection with hopes of improving patient outcomes and overall public health awareness surrounding HPV-related diseases.
Which are the best cities for genital warts clinical trials?
When it comes to clinical trials focused on genital warts, San Francisco stands out as a leading city for research. With one active trial currently underway, the study explores the effectiveness of treatments like the nonavalent human papillomavirus vaccine and others. As individuals seek innovative solutions for managing genital warts, San Francisco provides opportunities to participate in cutting-edge research that may lead to advancements in treatment options and improved outcomes.
Which are the top treatments for genital warts being explored in clinical trials?
Clinical trials are actively exploring various treatments for genital warts, aiming to provide effective solutions for patients. Among the top contenders is imiquimod, a commonly used topical cream that has shown promise in combating these pesky warts. Another treatment being investigated is sinecatechins, an ointment derived from green tea extract with potential antiviral properties. Additionally, researchers are studying the efficacy of podofilox gel as a targeted therapy for genital warts. With ongoing clinical trials and advancements in medical research, new breakthroughs may soon revolutionize the management of this common sexually transmitted infection (STI).
What are the most recent clinical trials for genital warts?
Recent clinical trials have focused on evaluating the effectiveness of a nonavalent human papillomavirus (HPV) vaccine for treating genital warts. This groundbreaking vaccine, currently in Phase 1 and Phase 2 trials, aims to provide an innovative solution for individuals affected by this common sexually transmitted infection. By targeting multiple strains of HPV known to cause genital warts, researchers aim to develop a highly effective preventive measure that can significantly reduce the incidence and severity of these lesions. These promising developments bring hope for improved treatment options and enhanced quality of life for those living with genital warts.
What genital warts clinical trials were recently completed?
Recently, there have been several clinical trials investigating the treatment of genital warts. These trials aim to find new and effective therapies for this common sexually transmitted infection. Although specific completion dates were not provided, it is encouraging to see ongoing research in this area. As researchers continue to explore innovative approaches, they offer hope for individuals affected by genital warts and contribute to our understanding of how best to combat this condition.